Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Pharvaris Q3 EPS $(0.77) Beats $(0.82) Estimate
Pharvaris (PHVS) Stock Could Look Pricey Following Phase 3 Momentum
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44
Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - Slideshow
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44
Pharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC Says
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.